4-氰基-4-[（苯基硫代甲基）硫代]-2,5-二氧代-1-吡咯烷基酯戊酸 | 864066-74-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氰基-4-[（苯基硫代甲基）硫代]-2,5-二氧代-1-吡咯烷基酯戊酸
• 中文别名: RAFT聚合剂；4-氰基-4-(苯基硫代羰基硫基)戊酸N-琥珀酰亚胺酯；4-氰基-4-（苯基硫代硫代硫代）戊酸N-羟基琥珀酰亚胺酯；NHS保护的RAFT；试剂4-Cyano-4-(phenylcarbonothioylthio)pentanoicacidN-succinimidylester；4-氰基-4-（苯基硫代硫代硫代）戊酸-琥珀酰亚胺酯
• 英文名称: 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid N-succinimidyl ester
• 英文别名: 4-cyano-4-((thiobenzoyl)sulfanyl) pentanoicsuccinimide ester；SCPDB；(2,5-dioxopyrrolidin-1-yl) 4-(benzenecarbonothioylsulfanyl)-4-cyanopentanoate
• CAS: 864066-74-0
• 化学式: C₁₇H₁₆N₂O₄S₂
• 分子量: 376.457
• InChiKey: XQQHRPPQBDALBV-UHFFFAOYSA-N

物化性质

• 熔点：
  175-185°C
• 沸点：
  538.9±60.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  145
• 氢给体数：
  0
• 氢受体数：
  7

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  4-氰基-4-[（苯基硫代甲基）硫代]-2,5-二氧代-1-吡咯烷基酯戊酸 、 4,17-二(3-氨基丙基)-8,13-二(3-(二(3-氨基丙基)氨基)丙基)-4,8,13,17-四氮杂二十烷-1,20-二胺 以 二氯甲烷 为溶剂， 反应 48.0h， 以95%的产率得到
  参考文献：
  名称：

  Synthesis and Characterization of Dendrimer-Star Polymer Using Dithiobenzoate-Terminated Poly(propylene imine) Dendrimer via Reversible Addition-Fragmentation Transfer Polymerization

  摘要：

  Two new reversible addition-fragmentation transfer (RAFT) agents with 8 and 16 terminal dithiobenzoate groups on the surface of poly(propylene imine) dendrimers (generation 2.0 and 3.0, respectively) were prepared, and successively they were used in the RAFT polymerization to produce well-defined dendrimer-star polymers. The polymerization kinetics were confirmed to pseudo-first-order behavior. The polymerizations displayed excellent molecular weight control and produced polymer with low polydispersities (< 1.3). The synthetic method was also suitable for the preparation of dendrimerstar block copolymers.

  DOI：

  10.1021/ma050455e
• 作为产物：
  描述：

  苯二硫代甲酸 在 碘 、 二甲基亚砜 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 44.0h， 生成 4-氰基-4-[（苯基硫代甲基）硫代]-2,5-二氧代-1-吡咯烷基酯戊酸
  参考文献：
  名称：

  Synthesis and Characterization of Dendrimer-Star Polymer Using Dithiobenzoate-Terminated Poly(propylene imine) Dendrimer via Reversible Addition-Fragmentation Transfer Polymerization

  摘要：

  Two new reversible addition-fragmentation transfer (RAFT) agents with 8 and 16 terminal dithiobenzoate groups on the surface of poly(propylene imine) dendrimers (generation 2.0 and 3.0, respectively) were prepared, and successively they were used in the RAFT polymerization to produce well-defined dendrimer-star polymers. The polymerization kinetics were confirmed to pseudo-first-order behavior. The polymerizations displayed excellent molecular weight control and produced polymer with low polydispersities (< 1.3). The synthetic method was also suitable for the preparation of dendrimerstar block copolymers.

  DOI：

  10.1021/ma050455e

文献信息

• Fabrication of Reductive-Responsive Prodrug Nanoparticles with Superior Structural Stability by Polymerization-Induced Self-Assembly and Functional Nanoscopic Platform for Drug Delivery
  作者：Wen-Jian Zhang、Chun-Yan Hong、Cai-Yuan Pan

  DOI：10.1021/acs.biomac.6b00819

  日期：2016.9.12

  conversion allows direct application of the resultant prodrug nanoparticles without further purification; (3) Robust structures of the resultant prodrug nanoparticles, because the cross-linker was used as the comonomer, resulted in core-cross-linking simultaneously with the formation of the prodrug nanoparticles; (4) The drug content in the resultant prodrug nanoparticles can be accurately modulated just

  报道了一种用于在癌症化学疗法中制造聚合物药物递送系统的高效策略，聚合诱导的自组装（PISA）。双嵌段前药共聚物，PEG- b -P（MEO 2 MA- co-CPTM）作为大分子RAFT试剂通过PISA制备前药纳米颗粒。通过这种方法制造智能药物输送系统的优点如下：（1）在一个锅中以相对较高的浓度（100 mg / mL）同时完成聚合，自组装和药物封装；（2）几乎完全的单体转化允许直接应用所得的前药纳米颗粒而无需进一步纯化；（3）由于使用交联剂作为共聚单体，因此所得到的前药纳米颗粒具有稳固的结构，从而在前药纳米颗粒形成的同时导致了核交联。（4）仅通过调节MEO 2的进料摩尔比就可以精确地调节所得前药纳米颗粒中的药物含量。MA / CPTM在PEG- b - P（MEO 2 MA- co -CPTM）的合成中。使用不同的前药大分子CTA可获得直径相似但药物含量不同的前药纳米颗粒。考虑到长期的生
• [EN] COMPOSITIONS AND METHODS OF MANUFACTURING STAR POLYMERS FOR LIGAND DISPLAY AND/OR DRUG DELIVERY<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE FABRICATION DE POLYMÈRES EN ÉTOILE POUR L'AFFICHAGE DE LIGAND ET/OU L'ADMINISTRATION DE MÉDICAMENT
  申请人：AVIDEA TECH INC

  公开号：WO2020214858A1

  公开（公告）日：2020-10-22

  A star polymer of formula O[P1]-([X]-A[P2]-[Z]-[P3])n where O is a core; A is a polymer arm attached to the core; X is a linker molecule between the core and the polymer arm; Z is a linker molecule between the end of the polymer arm and P3; P1, P2 and P3 are each independently one or more pharmaceutically active compounds that act extracellularly or intracellularly, n is an integer number; [ ] denotes that the group is optional; and at least one of P1, P2 or P3 is present.

  一个星形聚合物的化学式为O[P1]-([X]-A[P2]-[Z]-[P3])n，其中O是一个核心；A是连接到核心的聚合物臂；X是核心和聚合物臂之间的连接分子；Z是连接到聚合物臂末端和P3之间的连接分子；P1、P2和P3分别是一个或多个药物活性化合物，可以在细胞外或细胞内起作用，n是一个整数；[ ]表示该组是可选的；并且至少有一个P1、P2或P3存在。
• Highly Ordered Nanoporous Films from Supramolecular Diblock Copolymers with Hydrogen-Bonding Junctions
  作者：Damien Montarnal、Nicolas Delbosc、Cécile Chamignon、Marie-Alice Virolleaud、Yingdong Luo、Craig J. Hawker、Eric Drockenmuller、Julien Bernard

  DOI：10.1002/anie.201504838

  日期：2015.9.14

  PMMA supramolecular polymers with molecular weights up to 30 kg mol−1 are synthesized and shown to form highly stable supramolecular diblock copolymers (BCPs) when mixed, in non‐polar solvents or in the bulk. Hierarchical self‐assembly of such supramolecular BCPs by thermal annealing affords morphologies with excellent lateral order, comparable to features expected from covalent diblock copolymer analogues

  我们设计了有效的前体，该前体将互补的缔合基团与出色的结合亲和力和硫代羰基硫基团结合在一起，从而实现了精确的RAFT聚合。分子量高达30 kg mol -1的定义明确的PS和PMMA超分子聚合物合成后显示在非极性溶剂或本体中混合时会形成高度稳定的超分子二嵌段共聚物（BCP）。此类超分子BCP通过热退火的分层自组装可提供具有优异侧向顺序的形貌，可与共价二嵌段共聚物类似物预期的特征相媲美。用质子溶剂简单洗涤所得材料会破坏超分子缔合，并选择性地溶解一种聚合物，从而提供了一种制备顺序良好的纳米多孔材料的简单方法，而无需进行交联或侵入性化学降解。
• PEPTIDE-BASED VACCINES, METHODS OF MANUFACTURING, AND USES THEREOF FOR INDUCING AN IMMUNE RESPONSE
  申请人：Avidea Technologies, Inc.

  公开号：US20200054741A1

  公开（公告）日：2020-02-20

  The present disclosure relates to novel peptide-based vaccines, methods of manufacturing the novel peptide-based vaccines and uses thereof for delivering peptide antigens to induce an immune response, and in particular a T cell response to a subject.

  本公开涉及新型基于肽的疫苗，制造该新型基于肽的疫苗的方法以及将其用于传递肽抗原以诱导免疫应答，特别是T细胞应答给受试者。
• [EN] ANTIBODY-POLYMER-CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS-POLYMÈRE
  申请人：BOGAZICI UNIV

  公开号：WO2021021062A1

  公开（公告）日：2021-02-04

  The present invention relates to antibody-polymer conjugates which have high drug carrying capacity and which can realize active targeting thanks to the antibody existing thereon.

  本发明涉及具有高药物载荷能力并且能够通过存在在其上的抗体实现活性靶向的抗体-聚合物共轭物。